Health Alt Week 12 Transcript Review

Health Alterations: Week 12 Overview

1. Autoimmune Disorders Discussed

  • Myasthenia Gravis (MG)

  • Guillain-Barré Syndrome (GBS)

2. Diagnoses Overview

  • Alzheimer's Disease

  • Parkinson's Disease

2.1. Course Resources

  • Course content for week 12 is available in Brightspace.

  • Readings for Myasthenia Gravis and Guillain-Barré Syndrome
      - These are not covered in the textbook or OER.

  • Practice tests for ATI (Assessment Technologies Institute)
      - Updated test plans (2026 version) were issued without advance notice.

3. Alzheimer's Disease

3.1. Common Observations

  • Short-term memory loss.

  • Confusion and disorientation.

  • Individuals may forget family members.

  • Aggressive behavior is sometimes noted.

  • Wandering may pose safety risks.

3.2. Challenges in Care

  • Difficult to reorient patients experiencing confusion.

  • Differentiation between Alzheimer's and general dementia.
      - Alzheimer's is a form of dementia characterized by specific degenerative changes in the brain.

  • Mixed dementia includes both vascular dementia and Alzheimer's disease.

3.3. Etiology and Risk Factors

  • Age: Common in individuals over 65.

  • Prevalence: 1 in 9 Americans over 65 affected.

  • Genetics: Certain genetic factors increase risk; e.g., presence of specific cholesterol transporting proteins.

3.4. Pathophysiology

  • Neurodegeneration due to abnormal buildup of proteins (amyloid plaques and tau tangles) impacts nerve function and brain structure over time, leading to symptoms.

3.5. Disease Prevention and Promotion

  • Importance of lifestyle choices in potentially lowering risk of dementia and Alzheimer's progression.

  • Promote cardiovascular health, manage chronic conditions (e.g., diabetes).

  • Engage in physical activities to maintain strength and balance, thus reducing fall risks.

  • Address food insecurity and mental health stressors affecting the elderly.

3.6. Diagnostic Tools and Testing

  • Mini-Mental Status Exam: Evaluates cognitive function.

  • Imaging (CT, MRI) to rule out other causes of symptoms.

  • Amyloid PET Scan: Detects amyloid proteins in the brain.

  • Genetic testing (e.g., APOE testing) to assess risk, but not definitive for diagnosis.

3.7. Treatment and Care Interventions

  • No known way to stop Alzheimer's; treatments focus on symptom management:
      - Cholinesterase Inhibitors: Improve acetylcholine function.
      - Antidepressants and antipsychotics for mood and behavioral symptoms as needed.

  • Supportive care with emphasis on family education and psychosocial supports.

  • Managing safety: Installing alarms for wandering patients, ensuring safe home environments.

4. Parkinson's Disease

4.1. Key Symptoms

  • Tremors: Often presenting as resting tremors, e.g., pill rolling.

  • Muscle Rigidity: Resistance to movement.

  • Bradykinesia/Akinesia: Slowed movement or inability to initiate movement.

  • Postural Instability: Leaning or shuffling gait.

4.2. Prevalence and Risk Factors

  • More common in men, onset usually after 40 years.

  • Environmental factors (pesticides, industrial chemicals) and traumatic brain injuries may contribute.

4.3. Diagnosis

  • Diagnosis typically includes clinical examination and may involve imaging to rule out other conditions.

  • Consider tests such as SPECT and DAT scans that evaluate dopamine transmission.

4.4. Treatment Approaches

  • Dopamine Agonists: Improve mobility and reduce symptoms.

  • Exercise Programs: Focus on strength training, yoga, and maintaining mobility.

  • Surgical options like deep brain stimulation may be considered in some patients.

4.5. Cognitive Dysfunction and Care Coordination

  • Close monitoring of cognitive functions and home safety.

  • Collaborate with interdisciplinary teams for holistic care solutions.

5. Myasthenia Gravis (MG)

5.1. Definition and Symptoms

  • Autoimmune disorder causing weakening of muscles due to blocked acetylcholine receptors.

  • Early symptoms commonly involve ocular (eyelid ptosis, diplopia) and bulbar (swallowing, speech) manifestations.

5.2. Peak Risk Factors

  • Prior autoimmune conditions like Graves disease, lupus, etc.

  • Family history of autoimmune disorders increases risk.

5.3. Diagnosis

  • Testing for acetylcholine receptor antibodies and possibly MUsk antibodies is crucial.

  • Electromyography (EMG) tests to evaluate nerve and muscle communication.

5.4. Treatments

  • Anticholinesterase agents: Assist muscle contraction by blocking acetylcholine breakdown.

  • Immunosuppressants: Reduce antibody production hampering communication.

  • Thymectomy: In some populations, this can improve outcomes.

6. Guillain-Barré Syndrome (GBS)

6.1. Overview

  • Acute autoimmune disorder involving rapid-onset muscle weakness and paralysis, often post-viral or post-surgery.

  • Affects myelin sheath impacting sensory transmissions and motor functions.

6.2. Symptoms

  • Commonly ascending weakness, starting in lower extremities and moving to the upper body.

  • Autonomic instability can occur, affecting respiratory functions.

6.3. Diagnosis and Management

  • Cerebrospinal fluid analysis reveals elevated protein with normal white blood cell counts.

  • EMG shows slowed nerve conduction.

6.4. Treatment Options

  • Plasmapheresis: Remove harmful antibodies.

  • IV Immunoglobulin (IVIG): Provides healthy antibodies.

  • Supportive care including respiratory therapy and close monitoring.

6.5. Recovery and Considerations

  • Recovery often spans weeks to months, with ongoing physical therapy required for strength rebuild.